• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

The Most Promising Cancer-Fighter In Years
For a while now, I’ve been recommending a powerful antioxidant with the unpronounceable name, pyrroloquinoline quinine – or PQQ for short. And although I recommend this compound to almost everyone who comes to see me at my wellness clinic in South Florida because of its energy-giving qualities, I’ve also observed its extraordinary power to fight cancer. For years, I’ve seen PQQ work wonders with my older patients, because it keeps you feeling young by giving your cells extra energy. PQQ was first discovered back in 1979 by a team of Japanese scientists, who knew little about the substance, except that i...
Source: Al Sears, MD Natural Remedies - March 24, 2015 Category: Complementary Medicine Authors: Andrew Britton Tags: Anti-Aging antioxidants Cancer energy Source Type: news

Rethinking Retirement in the 21st Century
Conclusion In the 21st century, many seniors are not retiring from something. Instead, retirement is an opportunity for reinventing, reimagining and reconnecting to one's self, family, friends and community. Robert Browning once wrote, "Grow old along with me! The best is yet to be." By investing in your physical, mental and financial health today, you can help ensure that your best years are just ahead. Rear Admiral Susan Blumenthal, M.D., M.P.A. (ret.) is the Public Health Editor of The Huffington Post. She is a Senior Fellow in Health Policy at New America and a Clinical Professor at Tufts and Georgetown University Sc...
Source: Healthy Living - The Huffington Post - May 1, 2015 Category: Consumer Health News Source Type: news

Janssen Announces U.S. FDA Approval of INVEGA HAFYERA ™(6-month paliperidone palmitate), First and Only Twice-Yearly Treatment for Adults with Schizophrenia
TITUSVILLE, N.J., Sept. 1, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved long-acting atypical antipsychotic INVEGA HAFYERA™ (6-month paliperidone palmitate), the first-and-only twice-yearly injectable for the treatment of schizophrenia in adults. Before transitioning to INVEGA HAFYERA™, patients must be adequately treated with INVEGA SUSTENNA® (1-month paliperidone palmitate) for at least four months, or INVEGA TRINZA® (3-month paliperidone palmitate) for at least one 3-month injection cycle.1 The FDA approval of INVEGA ...
Source: Johnson and Johnson - September 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news